Tepadina And Sodium Chloride is a drug owned by Adienne Sa. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 31, 2037. Details of Tepadina And Sodium Chloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9931458 | Multi chamber flexible bag and methods of using same |
May, 2037
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Tepadina And Sodium Chloride's patents.
Latest Legal Activities on Tepadina And Sodium Chloride's Patents
Given below is the list of recent legal activities going on the following patents of Tepadina And Sodium Chloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Initial letter Re: PTE Application to regulating agency | 29 Aug, 2025 | US9931458 |
| Patent Term Extension Application under 35 USC 156 Filed | 05 Jun, 2025 | US9931458 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 30 Sep, 2021 | US9931458 |
| Application ready for PDX access by participating foreign offices | 06 Apr, 2018 | US9931458 |
| Recordation of Patent Grant Mailed | 03 Apr, 2018 | US9931458 |
| Patent Issue Date Used in PTA Calculation | 03 Apr, 2018 | US9931458 |
| Issue Notification Mailed | 14 Mar, 2018 | US9931458 |
| Application Is Considered Ready for Issue | 23 Feb, 2018 | US9931458 |
| Dispatch to FDC | 23 Feb, 2018 | US9931458 |
| Issue Fee Payment Received | 20 Feb, 2018 | US9931458 |
US patents provide insights into the exclusivity only within the United States, but
Tepadina And Sodium Chloride is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Tepadina And Sodium Chloride's family patents as well as insights into
ongoing legal events
on those patents.
Tepadina And Sodium Chloride's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tepadina And Sodium Chloride's generic launch date based on the expiry of its last outstanding patent is estimated to be May 31, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tepadina And Sodium Chloride Generic API suppliers:
Thiotepa is the generic name for the brand Tepadina And Sodium Chloride. 11 different companies have already filed for the generic of Tepadina And Sodium Chloride, with Msn having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tepadina And Sodium Chloride's generic
Alternative Brands for Tepadina And Sodium Chloride
There are several other brand drugs using the same active ingredient (Thiotepa) as Tepadina And Sodium Chloride. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Shorla |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Thiotepa, Tepadina And Sodium Chloride's active ingredient. Check the complete list of approved generic manufacturers for Tepadina And Sodium Chloride
About Tepadina And Sodium Chloride
Tepadina And Sodium Chloride is a drug owned by Adienne Sa. Tepadina And Sodium Chloride uses Thiotepa as an active ingredient. Tepadina And Sodium Chloride was launched by Adienne in 2017.
Approval Date:
Tepadina And Sodium Chloride was approved by FDA for market use on 26 January, 2017.
Active Ingredient:
Tepadina And Sodium Chloride uses Thiotepa as the active ingredient. Check out other Drugs and Companies using Thiotepa ingredient
Dosage:
Tepadina And Sodium Chloride is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG | POWDER | Prescription | INTRAVENOUS |